Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy Volunteers

Phase 1 Completed 18 enrolled ViiV Healthcare GlaxoSmithKline · collab Shionogi · collab

Non-randomizedSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to determine whether there is a drug interaction between GSK1349572 and the HIV protease inhibitors Tipranavir/Ritonavir (TPV/RTV).

Timeline

Start: 2010-02-15
Primary completion: 2010-04-05
Completion: 2010-04-05

Publications

Background Song I, Borland J, Chen S, Guta P, Lou Y, Wilfret D, Wajima T, Savina P, Peppercorn A, Castellino S, Wagner D, Hosking L, Mosteller M, Rubio JP, Piscitelli SC. Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir. Eur J Clin Pharmacol. 2014 Oct;70(10):1173-9. doi: 10.1007/s00228-014-1732-8. Epub 2014 Aug 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dolutegravir	Other / unclassified	50 mg	—
Subject	Ritonavir	Other / unclassified	200 mg	—
Subject	Tipranavir	Small molecule	500 mg	—

Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy Volunteers

Summary

Timeline

Publications

Drugs

Indications